Development of potent inhibitors of botulinum neurotoxin type B.

J Med Chem

Département de Pharmacochimie Moléculaire et Structurale, INSERM U266--CNRS FRE2463, UFR des Sciences Pharmaceutiques et Biologiques 4, Avenue de l'Observatoire--75270 Paris Cedex 06, France.

Published: October 2003

Botulinum neurotoxins are the most potent toxins known to date. They are zinc-metalloproteases able to cleave selectively an essential component of neurotransmitter exocytosis, causing the syndrome of botulism characterized by a flaccid paralysis. There is a great interest in designing antagonists of the action of these toxins. One way is to inhibit their catalytic activity. In this study, we report the design of such inhibitors directed toward BoNT/B. A study of the S(1) subsite specificity, using several beta-amino thiols, has shown that this subsite prefers a p-carboxybenzyl moiety. The specificity of the S(1)' and S(2)' subsites was studied using two libraries of pseudotripeptides containing the S(1) synthon derived from the best beta-amino thiol tested. Finally, a selection of various non natural amino acids for the recognition of the "prime" domain led to the most potent inhibitor of BoNT/B described to date with a K(i) value of 20 nM.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm0300680DOI Listing

Publication Analysis

Top Keywords

development potent
4
potent inhibitors
4
inhibitors botulinum
4
botulinum neurotoxin
4
neurotoxin type
4
type botulinum
4
botulinum neurotoxins
4
neurotoxins potent
4
potent toxins
4
toxins zinc-metalloproteases
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!